Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...
A case of acute myeloid leukemia with mast cell differentiation (AML-MC) that subsequently fulfilled diagnostic criteria for mast cell leukemia (MCL), an aggressive type of systemic mastocytosis (SM), ...
What Is Ziftomenib, and Why Does It Matter? Ziftomenib, sold under the brand name Komzifti, is a new oral medicine approved to treat adults with a type of blood cancer called acute myeloid leukemia ...
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic ...
Impact of TP53 mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia. ORR, n (%); 95% CI 50 (54); 43.1, 64.2 21 (39); 25.9, 53.1 DOR, median ...
A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...
Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results